See more : Fission Uranium Corp. (0UW4.L) Income Statement Analysis – Financial Results
Complete financial analysis of Intersect ENT, Inc. (XENT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Intersect ENT, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- ADX Energy Ltd (ADX.AX) Income Statement Analysis – Financial Results
- Tungsten Corporation plc (TUNG.L) Income Statement Analysis – Financial Results
- Microvast Holdings, Inc. (MVSTW) Income Statement Analysis – Financial Results
- Qilian International Holding Group Limited (QLI) Income Statement Analysis – Financial Results
- CPE Technology Berhad (5317.KL) Income Statement Analysis – Financial Results
Intersect ENT, Inc. (XENT)
About Intersect ENT, Inc.
Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL, a steroid releasing implant to open the surgically enlarged sinus; PROPEL Mini, a releasing implant to treat patients undergoing frontal sinus surgery; and PROPEL Contour, a steroid releasing implant for the treatment of frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a sterile and single-use device, used to access and treat frontal, sphenoid sinus, and maxillary ostia in adults using a trans-nasal approach; and CUBE Navigation System, a virtual guidance platform for high precision ENT and ENT related skull-base surgeries. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was incorporated in 2003 and is headquartered in Menlo Park, California.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 106.75M | 80.55M | 109.14M | 108.47M | 96.30M | 78.71M | 61.59M | 38.59M | 17.93M | 5.86M |
| Cost of Revenue | 30.01M | 30.31M | 21.77M | 22.61M | 15.50M | 13.00M | 12.29M | 10.22M | 8.15M | 3.84M |
| Gross Profit | 76.74M | 50.25M | 87.37M | 85.86M | 80.80M | 65.71M | 49.31M | 28.36M | 9.78M | 2.03M |
| Gross Profit Ratio | 71.89% | 62.38% | 80.05% | 79.15% | 83.91% | 83.48% | 80.05% | 73.51% | 54.55% | 34.56% |
| Research & Development | 27.94M | 19.35M | 24.28M | 19.26M | 18.36M | 18.89M | 16.61M | 10.33M | 9.52M | 9.26M |
| General & Administrative | 0.00 | 98.55M | 108.48M | 91.60M | 80.05M | 72.93M | 59.64M | 36.11M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 122.07M | 98.55M | 108.48M | 91.60M | 80.05M | 72.93M | 59.64M | 36.11M | 0.00 | 0.00 |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 18.23M | 9.25M |
| Operating Expenses | 150.01M | 117.90M | 132.76M | 110.87M | 98.41M | 91.82M | 76.25M | 46.44M | 27.75M | 18.51M |
| Cost & Expenses | 180.02M | 148.21M | 154.54M | 133.48M | 113.90M | 104.82M | 88.53M | 56.67M | 35.90M | 22.35M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 125.00K | 7.00K | 156.00K |
| Interest Expense | 6.44M | 2.75M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 409.00K | 117.00K | 36.00K |
| Depreciation & Amortization | 4.81M | 2.84M | 3.90M | 1.88M | 1.46M | 1.17M | 826.00K | 583.00K | 505.00K | 351.00K |
| EBITDA | -150.08M | -67.14M | -39.09M | -21.04M | -14.90M | -24.06M | -25.81M | -17.37M | -17.75M | -15.98M |
| EBITDA Ratio | -140.59% | -83.35% | -35.82% | -19.39% | -15.47% | -30.56% | -41.90% | -45.02% | -98.97% | -272.52% |
| Operating Income | -154.89M | -67.65M | -45.39M | -25.01M | -17.60M | -26.11M | -26.94M | -18.08M | -17.97M | -16.49M |
| Operating Income Ratio | -145.10% | -83.98% | -41.59% | -23.05% | -18.28% | -33.17% | -43.74% | -46.85% | -100.20% | -281.17% |
| Total Other Income/Expenses | -6.44M | -5.08M | 2.40M | 2.08M | 1.24M | 889.00K | 306.00K | -284.00K | -403.00K | 120.00K |
| Income Before Tax | -161.33M | -72.74M | -42.99M | -22.92M | -16.36M | -25.22M | -26.63M | -18.36M | -18.37M | -16.37M |
| Income Before Tax Ratio | -151.13% | -90.29% | -39.39% | -21.13% | -16.99% | -32.05% | -43.24% | -47.59% | -102.44% | -279.12% |
| Income Tax Expense | -1.69M | -416.00K | 2.40M | 2.08M | 1.24M | 889.00K | 306.00K | 125.00K | -286.00K | 156.00K |
| Net Income | -159.64M | -72.32M | -42.99M | -22.92M | -16.36M | -25.22M | -26.63M | -18.36M | -18.37M | -16.37M |
| Net Income Ratio | -149.54% | -89.78% | -39.39% | -21.13% | -16.99% | -32.05% | -43.24% | -47.59% | -102.44% | -279.12% |
| EPS | -4.80 | -2.22 | -1.37 | -0.76 | -0.56 | -0.89 | -1.02 | -1.61 | -1.17 | -0.94 |
| EPS Diluted | -4.80 | -2.22 | -1.37 | -0.76 | -0.56 | -0.89 | -1.02 | -1.61 | -1.17 | -0.94 |
| Weighted Avg Shares Out | 33.27M | 32.62M | 31.39M | 30.31M | 29.12M | 28.42M | 26.16M | 11.38M | 15.66M | 17.47M |
| Weighted Avg Shares Out (Dil) | 33.27M | 32.62M | 31.39M | 30.31M | 29.12M | 28.42M | 26.16M | 11.38M | 15.66M | 17.47M |
Why Intersect ENT Shot 12% Higher on Friday
Intersect ENT Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Intersect ENT, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – XENT
Shareholder Alert: Ademi LLP investigates whether Intersect ENT, Inc. has obtained a Fair Price in its transaction with Medtronic
Intersect ENT (XENT) Reports Q2 Loss, Tops Revenue Estimates
Medtronic Expands Its ENT Portfolio With Intersect ENT Acquisition For $28.25/Share
Intersect ENT Reports Second Quarter 2021 Financial Results
Medtronic to Acquire Intersect ENT
A Preview Of Intersect ENT's Earnings
Intersect ENT (XENT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
U.S Nationwide Commercial Availability of the VenSure™ Balloon Sinus Dilation System and Cube™ Navigation System Highlight Intersect ENT's Continued Commitment to Providing Innovative, Solutions for Patients with Chronic Rhinosinusitis
Source: https://incomestatements.info
Category: Stock Reports
What were the peak quarterly and annual revenues for Intersect ENT?
Intersect ENT’s peak quarterly revenue was $32.8M in 2018(q4). Intersect ENT peak revenue was $109.1M in 2019. Intersect ENT annual revenue for 2020 was 80.6M, -26.19% growth from 2019. Intersect ENT annual revenue for 2021 was 106.7M, 32.52% growth from 2020.
How did COVID-19 impact Intersect ENT’s financial results?
Through the pandemic months of 2020, Intersect ENT’s business suffered a huge revenue decline as a result of hospitals suspending elective surgical procedures and significantly reducing ENT office visits.